Abstract
The GLAGOV study demonstrated that addition of evolocumab to existing optimal statin therapy produced intensive lowering of low-density lipoprotein cholesterol (LDL-C) to very low levels and regression of coronary atherosclerosis compared with continuing statin monotherapy. This open label extension
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
